Alternative splicing and retinal degeneration

Clinical Genetics

Volumn 84, Issue 2, 2013, Pages 142-149

  Liu, M M ^a   Zack, D J ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUT DE LA VISION   (France)

Author keywords

Alternative splicing; Retinal degeneration; Retinitis pigmentosa; Small molecules

Indexed keywords

ACLARUBICIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BENZOTHIAZOLE DERIVATIVE; BUTYRIC ACID; CIS ACTING ELEMENT; FR 901464; HERBOXIDIENE; MESSENGER RNA PRECURSOR; PLADIENOLIDE DERIVATIVE; RHODOPSIN; SRPIN 340; SUDEMYCIN DERIVATIVE; TAU PROTEIN; TG 003; TRANS ACTING FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN 165;

ALTERNATIVE RNA SPLICING; AMINO ACID SUBSTITUTION; AUTOSOMAL DOMINANT INHERITANCE; COL2A1 GENE; EXON SKIPPING; FRAMESHIFT MUTATION; GAIN OF FUNCTION MUTATION; GENE; GENE DELETION; GENE INSERTION; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PRPF3 GENE; PRPF31 GENE; PRPF8 GENE; RETINA DEGENERATION; RETINA DYSTROPHY; RETINITIS PIGMENTOSA; REVIEW; SPLICING DEFECT; STICKLER SYNDROME; USHER SYNDROME;

ALTERNATIVE SPLICING; RETINAL DEGENERATION; RETINITIS PIGMENTOSA; SMALL MOLECULES;

ALTERNATIVE SPLICING; ANIMALS; HUMANS; MUTATION; RETINITIS PIGMENTOSA; RNA ISOFORMS; RNA SPLICE SITES; SPLICEOSOMES;

EID: 84880152075     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12181     Document Type: Review

References (72)

1. Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH. Prevalence of retinitis pigmentosa in Maine. Am J Ophthalmol 1984: 97: 357-365.
2. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006: 368: 1795-1809.
3. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003: 72: 291-336.
4. Sakharkar MK, Chow VTK, Kangueane P. Distributions of exons and introns in the human genome. In Silico Biol 2004: 4: 387-393.
5. Black DL. Finding splice sites within a wildnerness of RNA. RNA 1995: 1: 763-771.
6. Blencowe BJ. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 2000: 25: 106-110.
7. Smith CWJ, Valcárcel J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem Sci 2000: 25: 381-388.
8. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009: 10: 741-754.
9. Johnson JM, Castle J, Garrett-Engele P et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003: 302: 2141-2144.
10. Xu Q, Modrek B, Lee C. Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic Acids Res 2002: 30: 3754-3766.
11. Li Q, Lee JA, Black DL. Neuronal regulation of alternative pre-mRNA splicing. Nat Rev Neurosci 2007: 8: 819-831.
12. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992: 90: 41-54.
13. Chang B, Khanna H, Hawes N et al. In-frame deletion in a novel centrosomal/ciliary protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse. Hum Mol Genet 2006: 15: 1847-1857.
14. D'Cruz PM, Yasumura D, Weir J et al. Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat. Hum Mol Genet 2000: 9: 645-651.
15. Kameya S, Hawes NL, Chang B et al. Mfrp, a gene encoding a frizzled related protein, is mutated in the mouse retinal degeneration 6. Hum Mol Genet 2002: 11: 1879-1886.
16. Haider NB, Naggert JK, Nishina PM. Excess cone cell proliferation due to lack of a functional NR2E3 causes retinal dysplasia and degeneration in rd7/rd7 mice. Hum Mol Genet 2001: 10: 1619-1626.
17. Bishop PN, Reardon AJ, McLeod D, Ayad S. Identification of alternatively spliced variants of type II procollagen in vitreous. Biochem Biophys Res Commun 1994: 203: 289-295.
18. Parma ES, Korkko J, Hagler WS, Ala-Kokko L. Key to the clinical diagnosis of an ocular variant of Stickler syndrome with minimal or no systemic manifestations. Am J Ophthalmol 2002: 134: 728-734.
19. Gupta SK, Leonard BC, Damji KF, Bulman DE. A frame shift mutation in a tissue-specific alternatively spliced exon of collagen 2A1 in Wagner's vitreoretinal degeneration. Am J Ophthalmol 2002: 133: 203-210.
20. Khanna H, Hurd TW, Lillo C et al. RPGR-ORF15, which is mutated in retinitis pigmentosa, associates with SMC1, SMC3, and microtubule transport proteins. J Biol Chem 2005: 280: 33580-33587.
21. Vervoort R, Lennon A, Bird AC et al. Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. Nat Genet 2000: 25: 462-466.
22. Fujita R, Buraczynska M, Gieser L et al. Analysis of the RPGR gene in 11 pedigrees with the retinitis pigmentosa type 3 genotype: paucity of mutations in the coding region but splice defects in two families. Am J Hum Genet 1997: 61: 571-580.
23. Demirci FYK, Radak AL, Rigatti BW, Mah TS, Gorin MB. A presumed missense mutation of RPGR causes abnormal RNA splicing with exon skipping. Am J Ophthalmol 2004: 138: 504-505.
24. Glaus E, Schmid F, Da Costa R, Berger W, Neidhardt J. Gene therapeutic approach using mutation-adapted U1 snRNA to correct a RPGR splice defect in patient-derived cells. Mol Ther 2011: 19: 936-941.
25. Schmid F, Glaus E, Cremers FPM et al. Mutation- and tissue-specific alterations of RPGR transcripts. Invest Ophthalmol Vis Sci 2010: 51: 1628-1635.
26. Vervoort R, Wright AF. Mutations of RPGR in X-linked retinitis pigmentosa (RP3). Hum Mutat 2002: 19: 486-500.
27. Wright RN, Hong DH, Perkins B. Misexpression of the constitutive Rpgr(ex1-19) variant leads to severe photoreceptor degeneration. Invest Ophthalmol Vis Sci 2011: 52: 5189-5201.
28. Hong DH, Pawlyk BS, Adamian M, Li T. Dominant, gain-of-function mutant produced by truncation of RPGR. Invest Ophthalmol Vis Sci 2004: 45: 36-41.
29. Neidhardt J, Glaus ÃE, Barthelmes D et al. Identification and characterization of a novel RPGR isoform in human retina. Hum Mutat 2007: 28: 797-807.
30. Donoso LA, Edwards AO, Frost AT et al. Clinical variability of Stickler syndrome. Surv Ophthalmol 2003: 48: 191-203.
31. Weidenhammer EM, Ruiz-Noriega M, Woolford JL. Prp31p promotes the association of the U4/U6 x U5 tri-snRNP with prespliceosomes to form spliceosomes in Saccharomyces cerevisiae. Mol Cell Biol 1997: 17: 3580-3588.
32. Makarova OV, Makarov EM, Liu S, Vornlocher HP, Lührmann R. Protein 61K, encoded by a gene (PRPF31) linked to autosomal dominant retinitis pigmentosa, is required for U4/U6*U5 tri-snRNP formation and pre-mRNA splicing. EMBO J 2002: 21: 1148-1157.
33. Vithana EN, Abu-Safieh L, Allen MJ et al. A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). Mol Cell 2001: 8: 375-381.
34. Wang L, Ribaudo M, Zhao K et al. Novel deletion in the pre-mRNA splicing gene PRPF31 causes autosomal dominant retinitis pigmentosa in a large Chinese family. Am J Med Genet A 2006: 121: 235-239.
35. Xia K, Zheng D, Pan Q et al. A novel PRPF31 splice-site mutation in a Chinese family with autosomal dominant retinitis pigmentosa. Mol Vis 2004: 10: 361-365.
36. Martinez-Gimeno M, Gamundi MJ, Hernan I et al. Mutations in the pre-mRNA splicing-factor genes PRPF3, PRPF8, and PRPF31 in Spanish families with autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 2003: 44: 2171-2177.
37. Audo I, Bujakowska K, Mohand-Said S et al. Prevalence and novelty of PRPF31 mutations in French autosomal dominant rod-cone dystrophy patients and a review of published reports. BMC Med Genet 2010: 11: 145-153.
38. Mordes D, Yuan L, Xu L et al. Identification of photoreceptor genes affected by PRPF31 mutations associated with autosomal dominant retinitis pigmentosa. Neurobiol Dis 2007: 26: 291-300.
39. Yuan L, Kawada M, Havlioglu N, Tang H, Wu JY. Mutations in PRPF31 inhibit pre-mRNA splicing of rhodopsin gene and cause apoptosis of retinal cells. J Neurosci 2007: 25: 748-757.
40. Deery EC, Vithana EN, Newbold RJ et al. Disease mechanism for retinitis pigmentosa (RP11) caused by mutations in the splicing factor gene PRPF31. Hum Mol Genet 2002: 11: 3209-3219.
41. McKie AB, McHale JC, Keen TJ et al. Mutations in the pre-mRNA splicing factor gene PRPC8 in autosomal dominant retinitis pigmentosa (RP13). Hum Mol Genet 2001: 10: 1555-1562.
42. Grainger RJ, Beggs JD. Prp8 protein: at the heart of the spliceosome. RNA 2005: 11: 533-557.
43. Chakarova CF, Hims MM, Bolz H et al. Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. Hum Mol Genet 2002: 11: 87-92.
44. Comitato A, Spampanato C, Chakarova C et al. Mutations in splicing factor PRPF3, causing retinal degeneration, form detrimental aggregates in photoreceptor cells. Hum Mol Genet 2007: 16: 1699-1707.
45. Gamundi MJ, Hernan I, Muntanyola M et al. Transcriptional expression of cis-acting and trans-acting splicing mutations cause autosomal dominant retinitis pigmentosa. Hum Mutat 2008: 29: 869-878.
46. Maita H, Kitaura H, Ariga H, Iguchi-Ariga SMM. Association of PAP-1 and Prp3p, the products of causative genes of dominant retinitis pigmentosa, in the tri-snRNP complex. Exp Cell Res 2005: 302: 61-68.
47. Keen TJ, Hims MM, McKie AB et al. Mutations in a protein target of the Pim-1 kinase associated with the RP9 form of autosomal dominant retinitis pigmentosa. Eur J Hum Genet 2002: 10: 245-249.
48. Tanackovic G, Ransijn A, Ayuso C et al. A missense mutation in PRPF6 causes impairment of pre-mRNA splicing and autosomal-dominant retinitis pigmentosa. Am J Hum Genet 2011: 88: 643-649.
49. Zhao C, Bellur DL, Lu S et al. Autosomal-dominant retinitis pigmentosa caused by a mutation in SNRNP200, a gene required for unwinding of U4/U6 snRNAs. Am J Hum Genet 2009: 85: 617-627.
50. Li N, Mei H, MacDonald IM, Jiao X, Hejtmancik JF. Mutations in ASCC3L1 on 2q11.2 are associated with autosomal dominant retinitis pigmentosa in a Chinese family. Invest Ophthalmol Vis Sci 2010: 51: 1036-1043.
51. Mordes D, Luo X, Kar A et al. Review pre-mRNA splicing and retinitis pigmentosa. Mol Vis 2006: 12: 1259-1271.
52. Graziotto JJ, Farkas MH, Bujakowska K et al. Three gene-targeted mouse models of RNA splicing factor RP show late-onset RPE and retinal degeneration. Invest Ophthalmol Vis Sci 2011: 52: 190-198.
53. Tanackovic G, Ransijn A, Thibault P et al. PRPF mutations are associated with generalized defects in spliceosome formation and pre-mRNA splicing in patients with retinitis pigmentosa. Hum Mol Genet 2011: 20: 2116-2130.
54. Cao H, Wu J, Lam S et al. Temporal and tissue specific regulation of RP-associated splicing factor genes PRPF3, PRPF31 and PRPC8--implications in the pathogenesis of RP. PLoS One 2011: 6: e15860.
55. Schmid F, Glaus E, Barthelmes D et al. U1 snRNA-mediated gene therapeutic correction of splice defects caused by an exceptionally mild BBS mutation. Hum Mutat 2011: 32: 815-824.
56. Hernan I, Gamundi MJ, Planas E et al. Cellular expression and siRNA-mediated interference of rhodopsin cis-acting splicing mutants associated with autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 2011: 52: 3723-3729.
57. Singh RK, Cooper TA. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 2012: 18: 472-482.
58. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012: 11: 125-140.
59. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008: 371: 2120-2133.
60. Chang JG, Hsieh-Li HM, Jong YJ et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 2001: 98: 9808-9813.
61. Andreassi C, Jarecki J, Zhou J et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001: 10: 2841-2849.
62. Hastings ML, Berniac J, Liu YH et al. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci Transl Med 2010: 1: 5ra12.
63. Kotake Y, Sagane K, Owa T et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007: 3: 570-575.
64. Webb TR, Joyner AS, Potter PM. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discov Today 2013: 18: 43-49.
65. Fan L, Lagisetti C, Edwards CC, Webb TR, Potter PM. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. ACS Chem Biol 2012: 6: 582-589.
66. Hartmann AM, Rujescu D, Giannakouros T et al. Regulation of alternative splicing of human tau exon 10 by phosphorylation of splicing factors. Mol Cell Neurosci 2001: 18: 80-90.
67. Ninomiya K, Kataoka N, Hagiwara M. Stress-responsive maturation of Clk1/4 pre-mRNAs promotes phosphorylation of SR splicing factor. J Cell Biol 2011: 195: 27-40.
68. Muraki M, Ohkawara B, Hosoya T et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 2004: 279: 24246-24254.
69. Karlas A, Machuy N, Shin Y et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 2010: 463: 818-822.
70. Nishida A, Kataoka N, Takeshima Y et al. Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun 2011: 2: 1-8.
71. Nowak DG, Amin EM, Rennel ES et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J Biol Chem 2010: 285: 5532-5540.
72. Chang JG, Yang DM, Chang WH et al. Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells. PLoS One 2011: 6: e18643.